KR20220006041A - 합성 종양용해성 lnp-레플리콘 rna 및 암 면역요법을 위한 용도 - Google Patents

합성 종양용해성 lnp-레플리콘 rna 및 암 면역요법을 위한 용도 Download PDF

Info

Publication number
KR20220006041A
KR20220006041A KR1020217032460A KR20217032460A KR20220006041A KR 20220006041 A KR20220006041 A KR 20220006041A KR 1020217032460 A KR1020217032460 A KR 1020217032460A KR 20217032460 A KR20217032460 A KR 20217032460A KR 20220006041 A KR20220006041 A KR 20220006041A
Authority
KR
South Korea
Prior art keywords
oncolytic virus
replicon rna
synthetic oncolytic
virus
synthetic
Prior art date
Application number
KR1020217032460A
Other languages
English (en)
Korean (ko)
Inventor
다렐 제이. 어바인
칼 대인 윗트럽
론 와이스
잉중 리
누르 무민
이조우 동
Original Assignee
메사추세츠 인스티튜트 오브 테크놀로지
오하이오 스테이트 이노베이션 파운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메사추세츠 인스티튜트 오브 테크놀로지, 오하이오 스테이트 이노베이션 파운데이션 filed Critical 메사추세츠 인스티튜트 오브 테크놀로지
Publication of KR20220006041A publication Critical patent/KR20220006041A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020217032460A 2019-03-08 2020-01-10 합성 종양용해성 lnp-레플리콘 rna 및 암 면역요법을 위한 용도 KR20220006041A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962815611P 2019-03-08 2019-03-08
US62/815,611 2019-03-08
PCT/US2020/013069 WO2020185293A1 (en) 2019-03-08 2020-01-10 Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy

Publications (1)

Publication Number Publication Date
KR20220006041A true KR20220006041A (ko) 2022-01-14

Family

ID=69526302

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217032460A KR20220006041A (ko) 2019-03-08 2020-01-10 합성 종양용해성 lnp-레플리콘 rna 및 암 면역요법을 위한 용도

Country Status (13)

Country Link
US (2) US11717548B2 (en17)
EP (1) EP3934673A1 (en17)
JP (1) JP2022524391A (en17)
KR (1) KR20220006041A (en17)
CN (1) CN113966221A (en17)
AU (1) AU2020233788A1 (en17)
BR (1) BR112021017637A8 (en17)
CA (1) CA3132714A1 (en17)
CO (1) CO2021013417A2 (en17)
IL (1) IL285963A (en17)
MX (1) MX2021010808A (en17)
SG (1) SG11202109514VA (en17)
WO (1) WO2020185293A1 (en17)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113509542A (zh) * 2021-04-20 2021-10-19 嘉晨西海(杭州)生物技术有限公司 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法
WO2023212618A1 (en) 2022-04-26 2023-11-02 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
CN115227674B (zh) * 2022-08-05 2023-07-04 武汉滨会生物科技股份有限公司 包封的溶瘤病毒遗传物质及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP4180057A1 (en) * 2010-07-06 2023-05-17 GlaxoSmithKline Biologicals S.A. Virion-like delivery particles for self-replicating rna molecules
EP3188760B1 (en) * 2014-09-05 2023-12-06 Novartis AG Lipids and lipid compositions for the delivery of active agents
DK3297637T3 (da) * 2015-05-21 2021-08-02 Ohio State Innovation Foundation Benzen-1,3,5-tricarboxamidderivater og anvendelser deraf

Also Published As

Publication number Publication date
US20240024394A1 (en) 2024-01-25
CA3132714A1 (en) 2020-09-17
JP2022524391A (ja) 2022-05-02
WO2020185293A1 (en) 2020-09-17
US20200281994A1 (en) 2020-09-10
BR112021017637A2 (en17) 2021-11-09
CO2021013417A2 (es) 2022-01-17
AU2020233788A1 (en) 2021-10-07
EP3934673A1 (en) 2022-01-12
US11717548B2 (en) 2023-08-08
BR112021017637A8 (pt) 2022-08-16
MX2021010808A (es) 2021-12-15
IL285963A (en) 2021-10-31
SG11202109514VA (en) 2021-09-29
CN113966221A (zh) 2022-01-21

Similar Documents

Publication Publication Date Title
KR20180097631A (ko) 핵산을 와우 및 전정 세포에 전달하기 위한 물질 및 방법
RU2744603C2 (ru) Композиции, повышающие число копий вектора (чкв), и способы их применения
CN110856724B (zh) 包含核酸及car修饰的免疫细胞的治疗剂及其应用
KR102550926B1 (ko) 이중 항체 구축물을 발현하는 aav를 포함하는 조성물 및 이들의 용도
KR20220006041A (ko) 합성 종양용해성 lnp-레플리콘 rna 및 암 면역요법을 위한 용도
AU2023214288A1 (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
KR20210043574A (ko) 푸소좀 조성물 및 이의 용도
KR101255419B1 (ko) 인플루엔자 바이러스의 다중 아형에 대한 신규 백신
AU2017248259A1 (en) Chimeric antigen receptor T cell compositions
CA2447450C (en) Corona-virus-like particles comprising functionally deleted genomes
CN107746845B (zh) 特异性靶向LAG-3基因的sgRNA和特异性敲除LAG-3基因的方法
KR20200032174A (ko) 강화된 키메라 항원 수용체 및 이의 용도
RU2771383C2 (ru) Контролируемая пищевым рационом экспрессия нуклеиновой кислоты, кодирующей нуклеазу cas9, и ее применения
KR20210154176A (ko) 표적화된 생체내 후성유전학적 억제에 의한 장기지속성 진통
KR20200089289A (ko) 비골수제거 골수 재건을 위한 방법 및 조성물
CN108379597B (zh) 一种基因载体及其用于治疗视网膜神经节细胞变性的基因治疗药物
CN107760680B (zh) 特异性靶向TIM-3基因的sgRNA和特异性敲除TIM-3基因的方法
KR20240022575A (ko) 아머링된 키메라 수용체 및 이의 사용 방법
KR20220058461A (ko) 모노머형 스트렙타비딘을 발현하는 균주 및 비오틴화된 화합물을 포함하는 암 세포 표적용 조성물
KR20060002745A (ko) 치료적 생성물의 전달을 위한 증식성 줄기세포 및전구세포에서의 후보 분자의 지속적 발현
RU2809724C2 (ru) Синтетический онколитический lnp-репликон рнк и применения для иммунотерапии злокачественных опухолей
CN115298307A (zh) 核酸调节元件的新组合及其方法和用途
CN114008209A (zh) Aav介导的枫糖尿症(msud)基因疗法
CN108159434B (zh) 一种基因载体及其用于治疗青光眼的基因治疗药物
KR20210102247A (ko) Crispr 수퍼-리프레서에 의한 생체내 합성 면역조절